24 certified Labor Condition Applications on file with the U.S. Department of Labor, FY2021–FY2026.
Since September 2025, DOL's Project Firewall opens H-1B investigations without waiting for a complaint. These checkpoints come from Janssen Global Services, LLC's own public LCA filings (FY2024–FY2026) — the same records an investigator pulls first.
Next end date: 2026-10-14. Employing an H-1B worker past the LCA end date without a new certified LCA is a strict-liability violation — the replacement LCA must be certified before the I-129 extension is filed.
Each worksite needs its own 10-business-day LCA notice and a PAF record of that posting; a move to a new area of intended employment needs a new LCA before the worker starts there.
Level I is the entry-level prevailing-wage tier and the band DOL's Project Firewall reviews first for misclassification (senior duties filed at an entry-level wage). The national share is 17%.
Median offered wage is 16% above the DOL prevailing wage across 14 recent certified LCAs. Paying at the floor is lawful, but it invites the question of whether the wage level itself is right.
No additional recruitment or non-displacement attestations apply.
Public DOL disclosure data can lag actual filings by a quarter. Descriptive only — not legal advice.
Yes — Janssen Global Services, LLC sponsors H-1B workers, with 24 certified LCAs on file (FY2021–FY2026), including 7 in FY2026. The median certified salary is $229,600 (P25 $187,175, P75 $297,050). With a 38% transfer share, this employer actively accepts H-1B transfers. 100% of its certified filings meet or exceed the prevailing wage.
Janssen Global Services, LLC H-1B sponsorship at a glance, from public U.S. DOL LCA disclosure data (FY2021–FY2026).
Certified LCAs are a prerequisite to H-1B petitions, not visa approvals; one LCA can cover multiple workers. Descriptive only — not legal advice.
The shaded band is the middle half of certified salaries (P25–P75); the bar spans the lowest to highest certified salary.
Levels I–IV are DOL prevailing-wage experience tiers; 92% of filings are senior-level (III–IV).
| Fiscal year | Certified | Denied | Withdrawn | Total |
|---|---|---|---|---|
| FY2021 | 4 | 0 | 0 | 4 |
| FY2022 | 5 | 0 | 0 | 5 |
| FY2024 | 4 | 0 | 0 | 4 |
| FY2025 | 4 | 0 | 0 | 4 |
| FY2026 | 7 | 0 | 0 | 7 |
Case dispositions from the U.S. DOL OFLC disclosure files. Withdrawn are LCAs that were certified and later withdrawn by the employer; they still count toward Total.
| Job title | Salary | Level | Location | Filed | Status |
|---|---|---|---|---|---|
VP, Therapeutic Area Market Access Leader, Oncology I-203-26167-019382 | $390,700/yr | IV | Raritan, NJ | Jun 16, 2026 | Certified |
Medical Director Oncology Hematology I-200-26156-985605 | $266,200/yr | IV | Raritan, NJ | Jun 05, 2026 | Certified |
Senior Principal Data Scientist Global Data Science I-200-26148-958715 | $211,100/yr | IV | Raritan, NJ | May 28, 2026 | Certified |
Director, Global Medical Affairs Lead I-200-26125-872121 | $250,000/yr | IV | Raritan, NJ | May 05, 2026 | Certified |
Senior Director Transactions Immunology, Acquisitions I-203-25360-511282 | $322,000/yr | IV | New Brunswick, NJ | Dec 26, 2025 | Certified |
Manager, Global RWE - Immunology I-200-25309-376446 | $180,000/yr | III | Raritan, NJ | Nov 05, 2025 | Certified |
Manager, Global RWE - Oncology I-200-25309-376509 | $170,000/yr | III | Raritan, NJ | Nov 05, 2025 | Certified |
Director, Alliance Management I-200-25258-310140 | $235,500/yr | IV | Titusville, NJ | Sep 15, 2025 | Certified |
Director Global Comm Strat Precision Medicine I-200-24355-562840 | $174,699/yr | IV | Raritan, NJ | Dec 20, 2024 | Certified |
Associate Director, Global Real World Evidence (RWE) I-200-24340-522299 | $190,000/yr | III | Raritan, NJ | Dec 05, 2024 | Certified |
Head of Market Access, Oncology I-203-24274-373203 | $372,000/yr | IV | Raritan, NJ | Sep 30, 2024 | Certified |
Senior Director, Transactions Immunology and Acquisitions I-203-24096-859204 | $312,300/yr | IV | New Brunswick, NJ | Apr 05, 2024 | Certified |
Senior Director Transactions Immunology, Acquisitions I-203-24005-619678 | $303,200/yr | IV | New Brunswick, NJ | Jan 05, 2024 | Certified |
Associate Director, Health Economics Modeling I-200-23332-526895 | $190,000/yr | III | Raritan, NJ | Nov 28, 2023 | Certified |
Director, Global Real-World Evidence Data Science Analytics I-200-22158-251835 | $225,000/yr | IV | Raritan, NJ | Jun 07, 2022 | Certified |
Sr. Director, Transactions Immunology, Acquisitions I-203-22124-132732 | $295,000/yr | IV | New Brunswick, NJ | May 03, 2022 | Certified |
Director, Global Data Science I-200-22102-063179 | $235,000/yr | IV | Raritan, NJ | Apr 12, 2022 | Certified |
Director, Global Strategic Marketing , Multiple Myeloma I-203-22098-049709 | $234,200/yr | IV | Bridgewater, NJ | Apr 07, 2022 | Certified |
Senior Global Medical Affairs Leader, Myeloid Malignancies I-200-22052-917326 | $350,200/yr | IV | Newton, PA | Feb 21, 2022 | Certified |
Associate Director, Global Market Access Oncology I-200-21133-312444 | $185,000/yr | IV | Raritan, NJ | May 13, 2021 | Certified |
Director, Global Commercial Strategy, Gastroenterology I-200-21083-170312 | $177,300/yr | II | Horsham, PA | Mar 24, 2021 | Certified |
One row per LCA case (its latest version), from U.S. DOL OFLC disclosure data. Salaries are the offered wage, converted to a yearly figure. Certified LCAs are not visa approvals.
Worker positions by LCA filing purpose, summed across FY2021–FY2026 disclosure records.
Most active filing months: May and Dec — useful for timing transfer conversations.
Attestations from the employer's own LCA filings (Form ETA-9035), as disclosed by the U.S. DOL.
2 states · 6 cities
The same DOL data on this page is what every H-1B sponsor must track for each worker. ElevateStaffing.ai automates it end-to-end:
Get the private PAF / LCA gap check for your own filings — free, one business day — then let ElevateStaffing.ai keep every LCA, PAF, I-9 and I-983 deadline audit-ready.
Get my private gap check →